National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Intraocular (Eye) Melanoma Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 12/05/2007



Purpose of This PDQ Summary






General Information






Cellular Classification






Classification and Stage Information






Iris Melanoma






Ciliary Body Melanoma






Small Choroidal Melanoma






Medium and Large Choroidal Melanoma






Extraocular Extension and Metastatic Intraocular Melanoma






Recurrent Intraocular Melanoma






Get More Information From NCI






Changes to This Summary (12/05/2007)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Cellular Classification

Primary intraocular melanomas originate from melanocytes in the uveal tract.[1] Four distinct cellular types are recognized in intraocular melanoma (revised Callendar classification):[2]

  1. Spindle A cells (spindle-shaped cells with slender nuclei and lacking visible nucleoli).
  2. Spindle B cells (spindle-shaped cells with larger nuclei and distinct nucleoli).
  3. Epithelioid cells (larger polygonal cells with one or more prominent nucleoli).
  4. Intermediate cells (similar to but smaller than epithelioid cells).

Most primary intraocular melanomas contain variable numbers of epithelioid, spindle A, and spindle B cells (mixed-cell melanomas). Pure epithelioid-cell primary melanomas are infrequent (approximately 3% of cases).[1] In the Collaborative Ocular Melanoma Study, mixed-cell type melanomas predominated (86% of cases).[3]

Several microscopic features can affect the prognosis of intraocular melanoma, including cell type, mitotic activity, lymphocytic infiltration, and, possibly, fibrovascular loops.[1] Cell type remains the most often used predictor of outcome following enucleation, with spindle A cell melanomas carrying the best prognosis and epithelioid cell melanomas carrying the worst.[1,4]

References

  1. Klintworth GK, Scroggs MW: The eye and ocular adnexa. In: Sternberg SS, ed.: Diagnostic Surgical Pathology. Philadelphia, Pa: Lippincott Williams & Wilkins, 1999, pp 994-6. 

  2. Grossniklaus HE, Green WR: Uveal tumors. In: Garner A, Klintworth GK, eds.: Pathobiology of Occular Disease: A Dynamic Approach. 2nd ed. New York, NY: M. Dekker, 1994, pp 1423-77. 

  3. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 125 (6): 745-66, 1998.  [PUBMED Abstract]

  4. McLean IW: Prognostic features of uveal melanoma. Ophthalmol Clin North Am 8 (1): 143-53, 1995. 

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov